Read this company snapshot
Daily valuation snapshot
Aurinia Pharmaceuticals Inc: source evidence dated 2026-10-09.
- Daily close (USD)
- $16.65
- Market capitalization (USD)
- $2,215,301,947.2
- Price / earnings (TTM)
- 7.05
- Price / book
- 3.6
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research AUPH in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research AUPH in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing AUPH with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $16.65 |
| Market capitalization (USD) | $2,215,301,947.2 |
| Price / earnings (TTM) | 7.05 |
| Price / book | 3.6 |
No matching rows. Clear the filter to see all records.
Read AUPH's valuation metrics
Company size
Aurinia Pharmaceuticals Inc's recorded market capitalization is $2,215,301,947.2. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
AUPH's recorded P/E is 7.05: about $7.05 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
AUPH's recorded price-to-book ratio is 3.6. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Aurinia Pharmaceuticals Inc with Aurora
Use the snapshot above to ask a specific question about AUPH. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow AUPH's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.